SCHEMBL30943705

SCHEMBL30943705

O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 18/20 1.00
PIK3CA P42336 4/20 1.00
MTOR P42345 3/20 1.00
PIK3R1 P27986 2/20 1.00
TDP1 Q9NUW8 1/20 1.00
PIK3CD O00329 2/20 0.65
CYP1A2 P05177 2/20 0.65
KDM4E B2RXH2 2/20 0.65
ALDH1A1 P00352 2/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
PDE2A O00408 1/20 0.65
PIK3C2A O00443 1/20 0.65
PIK3R2 O00459 1/20 0.65
PIK3C2B O00750 1/20 0.65
BRD4 O60885 1/20 0.65
PDE5A O76074 1/20 0.65
TP53 P04637 1/20 0.65
CYP3A4 P08684 1/20 0.65
CYP2D6 P10635 1/20 0.65
PIM1 P11309 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30943704 1.00 PRKDC (1.00) PRKDCPIK3CAMTORPIK3R1TDP1
SCHEMBL29374897 1.00 PRKDC (1.00) PRKDCPIK3CAMTORPIK3R1TDP1
SCHEMBL610237 1.00 PRKDC (1.00) PRKDCPIK3CAMTORPIK3R1TDP1
SCHEMBL31061492 0.96 PRKDC (1.00) PRKDCPIK3CAMTORPIK3R1TDP1
SCHEMBL3535232 0.89 PRKDC (1.00) PRKDCPIK3CAMTORPIK3R1TDP1
SCHEMBL3538224 0.88 PRKDC (1.00) PRKDCPIK3CAMTORPIK3R1TDP1
SCHEMBL3537126 0.85 PRKDC (0.78) PRKDCPIK3CAMTORPIK3R1TDP1
SCHEMBL31060675 0.85 PRKDC (1.00) PRKDCPIK3CAMTORPIK3R1TDP1
SCHEMBL3538463 0.85 PRKDC (0.78) PRKDCPIK3CAMTORPIK3R1TDP1
SCHEMBL3537842 0.85 PRKDC (1.00) PRKDCPIK3CAMTORPIK3R1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024129605-A1 SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2024-06-20 WO disclosed